Best Peptides for Fat Loss
A research-backed ranking of the most effective peptides for fat loss and body recomposition — from FDA-approved GLP-1 agonists to investigational metabolic peptides, with mechanisms, clinical data, and evidence levels for each compound.
Several peptides on this list are FDA-approved prescription medications. Others are investigational. This content is for educational and research purposes only. Consult a healthcare professional before beginning any protocol.
Fat loss peptides work through two fundamentally different pathways. The first — and most clinically validated — is appetite suppression via GLP-1 receptor agonism. Compounds like semaglutide and tirzepatide reduce caloric intake by acting on hunger centers in the brain and slowing gastric emptying. The second pathway is direct lipolysis stimulation via growth hormone signaling. Peptides like tesamorelin and AOD-9604 increase the breakdown of stored fat by elevating growth hormone or mimicking its fat-burning fragment. These two approaches can be complementary but carry different risk profiles and evidence levels.
The compounds below are ranked by the strength of published clinical evidence for fat loss, the magnitude of observed results, and practical considerations including safety and accessibility. FDA-approved compounds with large-scale human trial data are ranked highest. Each entry links to the full compound profile on PeptideHelp for detailed mechanism, protocol, and safety information.
1. Semaglutide — Most Proven Fat Loss Peptide
Semaglutide is a GLP-1 receptor agonist and the most extensively validated fat loss peptide in clinical medicine. FDA-approved for both type 2 diabetes (Ozempic) and chronic weight management (Wegovy), it has been studied in over 10,000 patients across the STEP clinical trial program. The STEP 1 trial demonstrated average weight loss of 14.9% of body weight at the 2.4mg weekly dose over 68 weeks — a result that fundamentally changed the medical approach to obesity treatment.
Semaglutide works by mimicking the GLP-1 hormone, which suppresses appetite through hypothalamic signaling, slows gastric emptying to extend satiety, and improves insulin sensitivity. Its 7-day half-life allows once-weekly dosing. Beyond weight loss, the SELECT cardiovascular outcomes trial showed a 20% reduction in major adverse cardiovascular events — making semaglutide the first weight loss treatment to demonstrate cardiovascular benefit.
The standard protocol begins at 0.25mg weekly, titrating up every 4 weeks to a target dose of 2.4mg. Common side effects include nausea (40–50% during titration), vomiting, and diarrhea — most resolve within 4–8 weeks. Semaglutide requires a prescription and medical supervision. For detailed comparisons with other GLP-1 agonists, see semaglutide vs tirzepatide.
2. Tirzepatide — Highest Weight Loss in Approved Medications
Tirzepatide is a dual GIP/GLP-1 receptor agonist that produced the highest weight loss of any FDA-approved medication. The SURMOUNT-1 trial showed average weight loss of 22.5% of body weight at the 15mg dose over 72 weeks — surpassing semaglutide by a significant margin. Approved for type 2 diabetes (Mounjaro, 2022) and weight management (Zepbound, 2023), tirzepatide represents the second generation of incretin-based weight loss therapy.
The dual mechanism is what differentiates tirzepatide. By activating both GLP-1 and GIP receptors simultaneously, it provides appetite suppression through GLP-1 while GIP receptor activation enhances insulin sensitivity and may improve fat metabolism through pathways that GLP-1 alone does not access. The GIP component may also moderate the nausea caused by delayed gastric emptying, potentially improving tolerability at high-efficacy doses.
Dosing begins at 2.5mg weekly, titrating up every 4 weeks to a maximum of 15mg. Side effect profile is similar to semaglutide — gastrointestinal symptoms predominate during titration. Tirzepatide requires a prescription. For a deeper comparison, see tirzepatide vs retatrutide.
3. Retatrutide — Highest Weight Loss in Clinical Trials (Investigational)
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 data published in the New England Journal of Medicine showed average weight loss of 24.2% of body weight at the 12mg dose over 48 weeks — the highest figure ever recorded in an obesity clinical trial. The addition of glucagon receptor activation increases energy expenditure and drives hepatic fat oxidation, meaning retatrutide both reduces caloric intake and increases caloric burn.
Phase 2 data also demonstrated rapid resolution of metabolic-associated steatotic liver disease (MASLD) in most participants, suggesting powerful effects on visceral and hepatic fat specifically. Retatrutide is currently in Phase III clinical trials and is not approved or available as a prescription medication.
The Phase 2 study used doses ranging from 1mg to 12mg weekly via subcutaneous injection. While the efficacy data is striking, Phase III results from larger, longer studies are needed to confirm these findings and establish the long-term safety profile. For comparisons, see semaglutide vs retatrutide.
4. Tesamorelin — FDA-Approved for Visceral Fat Reduction
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog and the only FDA-approved peptide specifically indicated for reducing visceral abdominal fat. Originally approved for HIV-associated lipodystrophy, it works by stimulating the pituitary to release natural growth hormone, which in turn drives lipolysis — the breakdown of stored triglycerides in fat cells, with preferential effects on visceral (deep abdominal) fat stores.
Clinical trials showed that tesamorelin reduced visceral adipose tissue by approximately 15–18% over 26 weeks. Unlike GLP-1 agonists, tesamorelin does not primarily suppress appetite — it directly mobilizes stored fat. This makes it a different tool with a different use case. It is particularly valued by individuals who want to reduce visceral fat while preserving or building lean mass, since elevated growth hormone supports protein synthesis and muscle retention.
Standard dosing is 2mg daily via subcutaneous injection. Tesamorelin may raise IGF-1 levels and blood glucose in some individuals, so monitoring is important. It does not cause the nausea and GI effects associated with GLP-1 agonists. Tesamorelin is a prescription medication.
5. AOD-9604 — GH Fragment for Fat Loss Without GH Side Effects
AOD-9604 is a modified fragment of human growth hormone (amino acids 176–191) specifically designed to retain the fat-burning properties of GH while eliminating the muscle-building and blood-sugar-elevating effects. This selective mechanism makes it an appealing option for individuals who want GH-mediated fat loss without the broader hormonal impact of full GH or GH secretagogues.
AOD-9604 stimulates lipolysis and inhibits lipogenesis (new fat formation) by mimicking the way natural growth hormone regulates fat metabolism. Animal studies showed significant reductions in body fat without affecting blood glucose or IGF-1 levels. Human clinical trials showed modest but statistically significant weight loss over 12 weeks, though the magnitude was smaller than GLP-1 agonists.
Research protocols use 250–500mcg daily via subcutaneous injection, typically administered in the morning on an empty stomach. AOD-9604 has a favorable safety profile in clinical trials with no significant adverse effects reported. It is not FDA-approved and remains investigational.
6. MOTS-c — Mitochondrial Peptide for Metabolic Health
MOTS-c is a mitochondria-derived peptide that acts as a metabolic regulator, improving cellular energy utilization and insulin sensitivity. Unlike the appetite-suppressing approach of GLP-1 agonists or the direct lipolysis of GH-related peptides, MOTS-c works at the cellular level by activating AMPK (a key metabolic sensor) and improving how cells process glucose and fatty acids for energy.
Research in animal models has shown that MOTS-c prevents diet-induced obesity, improves glucose tolerance, and enhances exercise performance. It may be particularly relevant for individuals with metabolic dysfunction or insulin resistance, as it targets the underlying cellular inefficiency that drives fat storage. Human research is still in early stages.
Research protocols typically use 5–10mg administered subcutaneously 2–3 times per week. MOTS-c is investigational and not FDA-approved. Early safety data is favorable, but long-term human data is limited.
Fat Loss Peptides Comparison Table
| Peptide | Primary Benefit | Dosage Range | Evidence Level |
|---|---|---|---|
| Semaglutide | Appetite suppression (14.9% weight loss) | 0.25–2.4mg/week | Very Strong (FDA-approved, 10K+ patients) |
| Tirzepatide | Dual agonist (22.5% weight loss) | 2.5–15mg/week | Very Strong (FDA-approved) |
| Retatrutide | Triple agonist (24.2% weight loss) | 1–12mg/week | Strong (Phase II/III trials) |
| Tesamorelin | Visceral fat reduction via GH | 2mg/day | Very Strong (FDA-approved) |
| AOD-9604 | GH-fragment lipolysis | 250–500mcg/day | Moderate (human trials, modest results) |
| MOTS-c | Mitochondrial metabolic regulation | 5–10mg 2–3x/week | Emerging (animal + early human data) |
How to Choose the Right Fat Loss Peptide
The most important factor is whether you are primarily looking to reduce overall body weight or specifically target visceral abdominal fat. For overall weight loss, the GLP-1 agonists (semaglutide and tirzepatide) are the clear leaders — they have the strongest clinical evidence and produce the largest weight loss. Both require a prescription and medical monitoring. Between them, tirzepatide produces greater weight loss but semaglutide has a longer real-world safety track record.
For targeted visceral fat reduction while preserving muscle mass, tesamorelin is the best evidence-based choice. For individuals seeking a milder, non-prescription approach with a favorable side effect profile, AOD-9604 offers GH-mediated fat loss without the broader hormonal effects. MOTS-c is the most forward-looking option for metabolic optimization but has the least human data. Consider stacking a GLP-1 agonist with resistance training and high protein intake to mitigate lean mass loss — the most significant drawback of appetite-based fat loss approaches.
Frequently Asked Questions
What is the most effective peptide for fat loss?
Semaglutide is the most effective peptide for fat loss based on clinical trial data, producing average weight loss of 14.9% of body weight over 68 weeks. Tirzepatide produced even greater results at 22.5%. Both are FDA-approved prescription medications and require medical supervision.
Can peptides help lose belly fat specifically?
Tesamorelin is the only peptide FDA-approved specifically for reducing visceral abdominal fat. It works by stimulating growth hormone release, which preferentially mobilizes visceral fat stores. GLP-1 agonists also reduce visceral fat as part of overall weight loss, though not through targeted mechanisms.
Are fat loss peptides safe?
FDA-approved GLP-1 agonists like semaglutide and tirzepatide have well-characterized safety profiles from large clinical trials. Common side effects include nausea, vomiting, and diarrhea, primarily during dose titration. Non-FDA-approved peptides like AOD-9604 have more limited safety data.
Do fat loss peptides cause muscle loss?
GLP-1 agonists can cause lean mass loss — approximately 25–40% of total weight lost may be lean tissue. This can be mitigated with resistance training and adequate protein intake of 1.2–1.6g per kg daily. GH-related peptides like tesamorelin may actually help preserve lean mass during fat loss.
What is the difference between GLP-1 peptides and GH peptides for fat loss?
GLP-1 peptides primarily reduce fat by suppressing appetite and reducing caloric intake. GH-related peptides like tesamorelin and AOD-9604 work by directly increasing lipolysis — the breakdown of stored fat. GLP-1 agonists produce significantly greater total weight loss, while GH peptides may better preserve muscle mass.
Further Reading & Research
Explore independent research databases and regulatory resources.
Medical Disclaimer: Several compounds discussed on this page are FDA-approved prescription medications. Others are investigational. This content is for educational and research purposes only and does not constitute medical advice. Do not use any compound without consulting a licensed healthcare provider.